KEGG   DRUG: MepolizumabHelp
Entry
D04923                      Drug                                   

Name
Mepolizumab (USAN/INN);
Mepolizumab (genetical recombination) (JAN);
Nucala (TN)
Product
Class
Other
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 
ATC code: 
Activity
Antiasthmatic, Anti-IL-5 antibody
  Disease
Severe asthma (eosinophilic phenotype) [DS:H00079]
Comment
Monoclonal antibody
Target
IL5 [HSA:3567] [KO:K05428]
  Pathway
Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX09 Mepolizumab
      D04923  Mepolizumab (USAN/INN)
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Respiratory Tract Agents, Other
   Mepolizumab
    D04923  Mepolizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D04923  Mepolizumab (USAN/INN); Mepolizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  Class I cytokines
   interleukin 5
    Mepolizumab
     D04923  Mepolizumab (USAN/INN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D04923
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04923
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04923
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04923
BRITE hierarchy
Other DBs
CAS: 
196078-29-2
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system